+34 620 10 75 37info@nanbiosis.com

01 Mar

01 Mar

Reaching for the unreachable: New efforts to treat Lysosomal Storage Diseases

NANBIOSIS researchers pioneer novel treatments for Lysosomal Storage Diseases utilizing[...]

SEE ALL NEWS

Cutting-edge Biomedical Solutions

What are our  “Cutting-Edge Biomedical Solutions”

Integrated solutions to advanced challenges faced by biomedical researchers in nanomedicine, tissue engineering and regenerative medicine, diagnostic and medical device, that includes design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological point of view up to preclinical validation.

Complementing our list of “Cutting-Edge Biomedical Solutions” we offer a “Quallity Control and Regulatory Affair” Advisory Service

Contact us

 

Customized Biomolecules

Customized biomolecules production & validation

Design & Production of biomolecules: Customized design and production services of biological molecules for Tissue Engineering, Intelligent Devices, Implants, and specially Therapeutic Nanoconjugates and Biosensors reagents. Applications such as therapeutic agents, targeting, surfaces functionalization (tissue engineering or scaffolds and biosensors), IVD reagents.

Validation: Purification, characterization, chemical modifications and preservation of the developed biomolecules. Assays development and validation. Biomolecules functionalization and up-scaling.

Main Services are:

Contact us

Customized nanomedicines production & Preclinical Validation
 

Customized nanomedicines production & Preclinical Validation

Design & Production of nanomedicines: Supply nanomaterials, nanoconjugates and nanoencapsulation of active ingredients for applications in Nanomedicine: therapy, drug delivery, contrast agents (MRI, fluorescence) , theragnostic & reagents.

Preclinical Validation: Preclinical characterisation of nanomedicines including physicochemical properties, in vitro and in vivo biological properties. Immunology, toxicology and efficacy with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions. Biodistribution and metabolization follow up in animal models by NMR spectroscopy in tissues & biofluids.

Main Services are:

Customized biomaterials production & Preclinical Validation

Customized biomaterials production & Preclinical Validation 

Design & Production of biomaterials: Design and production of scaffolds for tissue engineering using 3D printing technologies and others.

Preclinical Validation: Preclinical validation of biomaterials, implants and surface coatings including surface and mechanical characterization and in vitro, biofilm and antibacterial properties studies of implants and in vivo biological properties with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions.

Main Services are:

  • Production of biomaterials and scaffolds by 3D printing (under development): Scaffolds and biomaterials production using different materials and  techniques including the 3D bioprinting for regenerative medicine and tissue engineering.
  • Physicochemical, mechanical and surface characterization of biomaterials (under development): Mechanical, surface composition and surface characteristics by using the most sophisticated equipment and taking advantage of the expertise of scientist internationally recognized in the matter. This includes standard mechanical and surface composition studies.
  • In vitro and in vivo Characterization of Biomaterials (under development): NANBIOSIS offers a complete set of solutions up to the preclinical stage with a range of animal models. Our study plans are tailored to meet the demands of each biomaterial based medical product, developed in collaboration with the user, under either GLP and non-GLP conditions. All of this is possible thanks to our access to the most sophisticated equipment and taking advantage of the expertise of scientists internationally recognized in the matter.
  • In silico modelling (under development): NANBIOSIS supplies expertise in customized computational solutions for different tissues (cardiovascular system, human eye and others). Mainly expertise in the numerical-experimental models and experimental electrophysiology processing and modelling in cardiology and modelling of functional behaviour of tissues and organs is offered.

Contact us

Diagnostics Devices Development & Validation

Diagnostics Devices Development & Validation 

In vitro diagnostics & biomarkers & organ-on-a chip: Development and validation of prototypes, biosensing devices, organ-on-a chip devices for diagnostic. Production of bioreceptors against identified biomarkers. Discovery of biomarkers for diagnostic, follow-up and prognostic of diseases by NMR spectroscopy in biofluids and tissues.

In vivo Bioimaging diagnostics & Validation: In vivo validation of contrast agents and development of nanoconjugates as contrast agents for MRI and fluorescence.

Main services are:

  • Affinity biomolecules production for diagnostics (under development): production and characterization of affinity receptors and reagents for in vitro diagnostic devices.
  • In vitro diagnostic Development & Validation (under development): Core Facilities in nanofabrication, biosensors development, microfluidics, bionano characterization and micro-nano technologies in Spain. NANBIOSIS supported the whole MNBS fabrication steps of the device and validation procedures of the developed IVD.
  • Biomarker’s discovery (under development): Discovery and quantification of biomarkers by NMR. Singular facilities for acquiring unique metabolic profiles of biofluids, cell lines and tissues by NMR techniques and others.
  • Organ-on-a-chip devices development & Validation (under development): Experts in microfluidics for the device’s development & validation. The customization of the technology needed, the design of the devices, the complete fabrication process, their encapsulation, micro electrodes incorporation and the characterization and test up to the technological support on the experimental uses. Several organ-on-a-chip devices have been developed based on organoids and IPScells, scaffolds and others).
  • Data-enabled techniques (under development): Experts related to the use of personalized virtual and augmented reality for pre-intraoperative planning, data-intensive methodologies, artificial intelligence techniques (machine learning) for virtual patients’ personalization (digital twins).
  • Nanoparticles as contrast agents for MRI and OCT (under development): NANBIOSIS approach offers novel synthetic strategies and experimental setup for the advanced preparation of a wide range of nanoparticles for MRI contrast agents.
  • Nanoconjugates for fluorescence (under development): NANBIOSIS approach offers novel synthetic strategies and experimental setup for the advanced preparation of a wide range of nanoparticles for fluorescence.
Contact us

About Us

The Spanish Strategy for Science, Technology and Innovation includes the “National Scientific and Technological Infrastructure Map (ICTS)”. These ICTS are large installations, resources, facilities and services, unique in its kind, that are dedicated to cutting edge and high quality research and technological development, as well as to promote exchange, transmission and preservation of knowledge, technology transfer and innovation. These are facilities of different scientific areas distributed throughout the Spanish territory and are OPEN to competitive access to users of the whole research community in the public and private sector. NANBIOSIS inclusion in the Map of ICTS was recognized by the Spanish Government in 2014 and periodically renewed till now.

NANBIOSIS is managed under the ISO9001 certification for standard quality control system:

QUALITY POLICY

 ISO 9001:2015 Certification 

 

Order request Access protocolSurvey

Next Events

Our figures

0

Units

0

Scientists linked to ICTS

0

Projects since 2008

0

Services since 2008

0

Publications since 2008

0

M€ investment